ELIAS JOSEPH JABBOUR to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.451
-
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
Score: 0.131
-
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother. 2015 May; 16(7):999-1007.
Score: 0.112
-
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):646-56.
Score: 0.101
-
Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
Score: 0.084
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
Score: 0.023